Nyxoah תשתתף בכנס Stifel 2025 Healthcare
מונט-סנט-גיברט, בלגיה, 3 בנובמבר 2025, (GLOBE NEWSWIRE) :
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת
טכנולוגיות רפואיות המפתחת חלופות טיפול פורצות דרך לדום נשימה בשינה (OSA), הודיעה היום כי החברה תשתתף בכנס
Stifel 2025 Healthcare ביום שלישי, 11 בנובמבר 2025. החברה מתוכננת להציג בשעה
9:20 בבוקר שעון מזרח באותו יום באמצעות שידור אינטרנטי.
Nyxoah
to Participate in the Stifel 2025 Healthcare Conference
Mont-Saint-Guibert,
Belgium – November 3, GLOBE NEWSWIRE
–
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops
breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today
announced that the Company will participate in the Stifel 2025 Healthcare
Conference on Tuesday, Nov. 11, 2025. The Company is scheduled to present at
9:20am Eastern Time the same day via webcast.
A live
webcast of the event can be accessed by visiting Nyxoah’s Investor Relations
website and will be available for replay following the events. The Company will
also be available for 1x1 meetings with institutional investors attending the
event.
About
Nyxoah
Nyxoah is a
medical technology company focused on the development and commercialization of
innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system,
a patient-centered, leadless and battery-free hypoglossal neurostimulation
therapy for OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy
restful nights and feel enabled to live their life to its fullest.
Following
the successful completion of the BLAST OSA study, the Genio system received its
European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext
Brussels in September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the
expansion of its therapeutic indications to Complete Concentric Collapse (CCC)
patients, currently contraindicated in competitors’ therapy. Additionally, the
Company announced positive outcomes from the DREAM IDE pivotal study and U.S.
FDA approval of a Premarket Approval application.
Caution – CE marked
since 2019. FDA approved in August 2025 as prescription-only device.
תגובות
הוסף רשומת תגובה